Loading...
•
Dec 31, 2021
Iovance Q4 2021 Earnings Report
Reported fourth quarter and full year financial results and corporate updates.
Key Takeaways
Iovance Biotherapeutics reported a net loss of $99.3 million for the fourth quarter of 2021, with research and development expenses at $75.6 million and general and administrative expenses at $23.8 million. The company's cash position at the end of 2021 was $602.1 million, expected to fund operations into 2024.
Iovance continued to build upon the strength of clinical data for TIL therapy in multiple solid tumor types and treatment settings throughout 2021.
Long-term clinical data for one-time treatment with lifileucel in metastatic melanoma was highlighted.
There is potential to increase response rates for TIL therapy in combination with pembrolizumab as an earlier treatment for melanoma, cervical and head and neck cancers.
An important proof-of-concept for Iovance TIL therapy in non-small cell lung cancer was achieved.
Forward Guidance
Iovance is focused on addressing FDA feedback regarding potency assays for lifileucel to support their planned BLA submission in the first half of the year. With late-stage clinical assets, a strong balance sheet, and investments in launch preparations, the company is well-positioned to execute its operating plan and deliver new treatment options while enhancing shareholder value.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...